hVIVO (LON:HVO) Trading Up 11.6% - Here's Why

hVIVO plc (LON:HVO - Get Free Report)'s stock price was up 11.6% during mid-day trading on Monday . The stock traded as high as GBX 7.90 ($0.11) and last traded at GBX 7.70 ($0.10). Approximately 2,959,781 shares changed hands during mid-day trading, an increase of 1% from the average daily volume of 2,936,445 shares. The stock had previously closed at GBX 6.90 ($0.09).

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on HVO shares. Peel Hunt reissued an "add" rating and issued a GBX 21 price objective on shares of hVIVO in a research note on Tuesday, July 29th. Shore Capital dropped their price objective on hVIVO from GBX 35 to GBX 25 and set a "buy" rating on the stock in a research note on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, hVIVO presently has an average rating of "Buy" and an average price target of GBX 23.

hVIVO Price Performance

The company has a current ratio of 1.61, a quick ratio of 1.16 and a debt-to-equity ratio of 33.86. The firm has a market cap of £54.12 million, a P/E ratio of 1,022.73 and a beta of 0.97. The firm has a 50-day simple moving average of GBX 9.27 and a 200-day simple moving average of GBX 12.

hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.